JP2010526303A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526303A5 JP2010526303A5 JP2010506711A JP2010506711A JP2010526303A5 JP 2010526303 A5 JP2010526303 A5 JP 2010526303A5 JP 2010506711 A JP2010506711 A JP 2010506711A JP 2010506711 A JP2010506711 A JP 2010506711A JP 2010526303 A5 JP2010526303 A5 JP 2010526303A5
- Authority
- JP
- Japan
- Prior art keywords
- set according
- treatment
- rheumatoid arthritis
- tnf
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 13
- 239000005557 antagonist Substances 0.000 claims 8
- 108010074051 C-Reactive Protein Proteins 0.000 claims 4
- 102100032752 C-reactive protein Human genes 0.000 claims 4
- 239000003435 antirheumatic agent Substances 0.000 claims 4
- 229960000074 biopharmaceutical Drugs 0.000 claims 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 4
- ZAVJTSLIGAGALR-UHFFFAOYSA-N 2-(2,2,2-trifluoroacetyl)cyclooctan-1-one Chemical compound FC(F)(F)C(=O)C1CCCCCCC1=O ZAVJTSLIGAGALR-UHFFFAOYSA-N 0.000 claims 2
- 208000006820 Arthralgia Diseases 0.000 claims 2
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 claims 2
- 108010008165 Etanercept Proteins 0.000 claims 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 2
- 206010023232 Joint swelling Diseases 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 229960002964 adalimumab Drugs 0.000 claims 2
- 229940005553 analgesics and anesthetics Drugs 0.000 claims 2
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 claims 2
- 229960005207 auranofin Drugs 0.000 claims 2
- 229960001799 aurothioglucose Drugs 0.000 claims 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 2
- 229960002170 azathioprine Drugs 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000875 corresponding effect Effects 0.000 claims 2
- 238000007435 diagnostic evaluation Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 229960000403 etanercept Drugs 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 229940015045 gold sodium thiomalate Drugs 0.000 claims 2
- 229960001743 golimumab Drugs 0.000 claims 2
- 229960002927 hydroxychloroquine sulfate Drugs 0.000 claims 2
- 239000003326 hypnotic agent Substances 0.000 claims 2
- 230000000147 hypnotic effect Effects 0.000 claims 2
- 229960000598 infliximab Drugs 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 210000001503 joint Anatomy 0.000 claims 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 2
- 229960000681 leflunomide Drugs 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 229940035363 muscle relaxants Drugs 0.000 claims 2
- 239000003158 myorelaxant agent Substances 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 238000004062 sedimentation Methods 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 claims 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 2
- 229960001940 sulfasalazine Drugs 0.000 claims 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91572407P | 2007-05-03 | 2007-05-03 | |
| PCT/US2008/062621 WO2008137828A1 (en) | 2007-05-03 | 2008-05-05 | Matrix marker model and methods for assessing and treating arthritis and related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010526303A JP2010526303A (ja) | 2010-07-29 |
| JP2010526303A5 true JP2010526303A5 (enExample) | 2012-01-26 |
Family
ID=39943976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506711A Pending JP2010526303A (ja) | 2007-05-03 | 2008-05-05 | 関節炎及び関連疾病を評価及び治療するためのマトリックスマーカーモデル及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100145901A1 (enExample) |
| EP (1) | EP2148934B1 (enExample) |
| JP (1) | JP2010526303A (enExample) |
| AT (1) | ATE550443T1 (enExample) |
| AU (1) | AU2008247388A1 (enExample) |
| CA (1) | CA2686260A1 (enExample) |
| WO (1) | WO2008137828A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3042202A1 (en) | 2013-09-03 | 2016-07-13 | Graham, L. Douglas | Treatment methods for rheumatoid arthritis |
| EP4502182A3 (en) * | 2018-01-24 | 2025-07-09 | Genentech, Inc. | Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra) |
| JP7593797B2 (ja) * | 2020-12-08 | 2024-12-03 | キヤノンメディカルシステムズ株式会社 | 解析装置、解析システム及び解析方法 |
| WO2023023338A1 (en) * | 2021-08-19 | 2023-02-23 | Navidea Biopharmaceuticals, Inc. | Compositions and methods for the treatment of rheumatoid arthritis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6187539A (ja) * | 1984-09-19 | 1986-05-02 | ヘルギ・ヴアルデイマーソン | 慢性関節リウマチ患者の予後を補助するための方法及びこのような患者の病態活動の評価を補助するための方法 |
| EP1212463A2 (en) * | 1999-09-08 | 2002-06-12 | The University Of British Columbia | Diagnostic and therapeutic methods in autoimmune disease |
| WO2002022013A1 (en) * | 2000-09-14 | 2002-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing condition of a joint and cartilage loss |
| US20060141547A1 (en) * | 2004-11-16 | 2006-06-29 | Das Hasi R | Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis |
| US7702469B2 (en) * | 2006-04-10 | 2010-04-20 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Systems and methods for predicting an individual's risk of developing rheumatoid arthritis |
-
2008
- 2008-05-05 JP JP2010506711A patent/JP2010526303A/ja active Pending
- 2008-05-05 EP EP08769291A patent/EP2148934B1/en not_active Not-in-force
- 2008-05-05 AU AU2008247388A patent/AU2008247388A1/en not_active Abandoned
- 2008-05-05 AT AT08769291T patent/ATE550443T1/de active
- 2008-05-05 WO PCT/US2008/062621 patent/WO2008137828A1/en not_active Ceased
- 2008-05-05 US US12/595,979 patent/US20100145901A1/en not_active Abandoned
- 2008-05-05 CA CA002686260A patent/CA2686260A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Halyabar et al. | Treatment withdrawal following remission in juvenile idiopathic arthritis: a systematic review of the literature | |
| Combe | Early rheumatoid arthritis: strategies for prevention and management | |
| Garnero et al. | Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept | |
| JP2014517279A5 (enExample) | ||
| RU2017126701A (ru) | Способ детекции нуклеосом, содержащих нуклеотиды | |
| JP2009511911A5 (enExample) | ||
| RU2013154566A (ru) | Способы анализа профиля активности болезни с целью проведения индивидуального лечения | |
| Matsuda et al. | Time lag between active joint inflammation and radiological progression in patients with early rheumatoid arthritis | |
| Hirata et al. | Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study | |
| JP2010526303A5 (enExample) | ||
| Elia et al. | Adult inflammatory bowel disease, physical rehabilitation, and structured exercise | |
| Hochberg | Early aggressive DMARD therapy: the key to slowing disease progression in rheumatoid arthritis | |
| EP2148934B1 (en) | Matrix marker model and methods for assessing and treating rheumatoid arthritis | |
| Wallbach et al. | Effects of SGLT2 inhibitors on parameters of renal venous congestion in intrarenal Doppler ultrasonography | |
| Kita et al. | Significant improvement in MRI-proven bone edema is associated with protection from structural damage in very early RA patients managed using the tight control approach | |
| Abdullayeva et al. | Assessment of the severity of ulcerative colitis: An effective pathway from invasive to non-invasive diagnosis | |
| Kulchytska et al. | WITH A COMBINATION OF ANKYLOSING SPONDYLITIS AND CROHNS DISEASE | |
| Katayama et al. | POS0481 BONE EDEMA IN MRI IS MORE ASSOCIATED WITH RAPID RADIOGRAPHIC PROGRESSION THAN CLINICALLY RELEVANT RADIOGRAPHIC PROGRESSION. | |
| Alshamary et al. | Comparison of the effects of Methotrexate and Etanercept on RANKL and OPG as Bone Metabolism Biomarkers in patients with Rheumatoid Arthritis | |
| Harrold | Association Between Anti-Citrullinated Protein Antibody Status, Erosive Disease and Healthcare Resource Utilization in Patients With RA | |
| RU2257840C1 (ru) | Способ оценки эффективности фармакотерапии при артериальной гипертонии | |
| RU2005116782A (ru) | Способ выбора лабораторных методов для прогнозирования развития посттравматических гнойно-воспалительных осложнений в ортопедии и травматологии | |
| García et al. | Does early treatment of Rheumatoid Arthritis lead to a better long-term prognosis? | |
| Lee et al. | Prognostic Factors among Patients Referred for Inpatient Rehabilitation after Cardiac Surgery | |
| Bayala et al. | Massive multi-fingered gangrene in a case of systemic scleroderma: a rare and disabling complication |